Maxim Group analyst Jason McCarthy maintained a Buy rating on Cassava Sciences (NASDAQ:SAVA) on Thursday, setting a price target of $190, which is approximately 216.03% above the present share price of $60.12.
McCarthy expects Cassava Sciences to post earnings per share (EPS) of -$0.13 for the third quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Cassava Sciences, with an average price target of $147.4.
The analysts price targets range from a high of $215 to a low of $100.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $0 and a net profit of -$5.14 million. The company's market cap is $2.41 billion.
According to TipRanks.com, Maxim Group analyst Jason McCarthy is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 15.5% and a 36.03% success rate.
Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.